Antisense Therapy Could Cover 76% of SCN2A Cases
Researchers propose a shared set of four antisense oligonucleotides to treat many people with SCN2A-related disorders rather than one patient at a time.
Updated on Nov. 5, 2026 in Biotech
Researchers led by Stephen Kingsmore of Cleveland Clinic designed antisense oligonucleotides, or ASOs, that target common genetic variations behind SCN2A-related disorders. Computational modeling suggests a panel of four ASOs could cover 76.2% of individuals in a reference population, according to a study in The American Journal of Human Genetics.
Why it matters
Individualized ASOs designed for a single patient's mutation may offer little therapeutic value for others, limiting access to bespoke genetic treatments. A reusable panel could make the approach far more broadly applicable if the candidates are validated.
Sequencing of 21 patients with SCN2A-related disorders found 10 (48%) with genetic configurations potentially compatible with one of two existing ASOs. Computational modeling estimated a four-ASO panel could cover 76.2% of 2,504 unrelated participants in the 1000 Genomes Project, though the additional candidates still require laboratory validation.
The players
Stephen Kingsmore
Stephen Kingsmore is a physician-scientist at Cleveland Clinic who led the study on designing shared antisense therapies for SCN2A-related disorders.
Cleveland Clinic
Cleveland Clinic is a major nonprofit academic medical center in Ohio whose researchers led the study.
The details
The approach targets shared haplotype sequences to selectively suppress expression from the chromosome carrying a harmful mutation, using sequencing that distinguishes the two inherited copies of a gene. Two ASOs were originally developed for individual children, and both showed sustained clinical improvements over two years, including one boy whose seizures fell by more than 90%.
Timeline
Sustained improvements in the original individualized trial children were observed over two years.
Roadmap
The study extends earlier individualized antisense trials that treated single children with SCN2A disorders by proposing a shared panel of ASOs. If the four-ASO candidates are validated, the strategy could shift bespoke genetic medicine toward reusable therapies.
If validated, a reusable panel of ASOs could offer a treatment option to patients whose specific mutations have no existing therapy. Families of people with SCN2A-related disorders would not need a custom drug developed for each individual child.
The takeaway
Reusable genetic therapies could make rare-disease treatment far more scalable, but only after the proposed ASO candidates clear laboratory and clinical validation.
Further reading
Explore more on Biotech developments shaping how genetic disorders may be treated across populations.
Source note: This article includes information reported by Inside Precision Medicine.
